Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Apricus Biosciences, Inc. (NASDAQ: APRI).

Full DD Report for APRI

You must become a subscriber to view this report.


Recent News from (NASDAQ: APRI)

Apricus Biosciences Reminds Shareholders to Vote Before the Special Meeting on December 14, 2018
Seeking Shareholder Approval for Proposed Merger with Seelos Therapeutics, Inc. SAN DIEGO, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, reminds shareholders to vote by...
Source: GlobeNewswire
Date: December, 10 2018 07:00
Apricus Biosciences reports Q3 results
Apricus Biosciences (NASDAQ: APRI ): Q3 GAAP EPS of -$0.12. More news on: Apricus Biosciences, Inc, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: October, 31 2018 16:52
Apricus Biosciences Provides Corporate Update and Third Quarter 2018 Financial Results
Company Merger with Seelos Therapeutics, Inc. Expected to Close in Fourth Quarter 2018 Apricus Shareholders Expected to Own ~15% of Estimated $94 Million Combined Company Valuation at Closing SAN DIEGO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a bioph...
Source: GlobeNewswire
Date: October, 31 2018 16:24
Apricus Biosciences beats by $0.02
Apricus Biosciences (NASDAQ: APRI ): Q2 EPS of -$0.10 beats by $0.02 . More news on: Apricus Biosciences, Inc, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 09 2018 16:41
Apricus Biosciences Provides Corporate Update and Second Quarter 2018 Financial Results
Company Enters Into Merger Agreement with Seelos Therapeutics, Inc. Apricus Shareholders Expected to Own ~14% of Combined Company Based on  Estimated $90 Million Valuation at Closing Merger Expected to Close in Fourth Quarter 2018 SAN DIEGO, Aug. 09, 2018 (GLOBE NEWSWIRE)...
Source: GlobeNewswire
Date: August, 09 2018 16:05
Apricus Bio up 29% premarket on merger with Seelos Therapeutics
Nano cap Apricus Biosciences (NASDAQ: APRI ) is up  29%  premarket on increased volume in response to its planned merger with privately held Seelos Therapeutics in an all-stock deal. Seelos shareholders will own ~86% of the new company while Apricus shareholders will own ~14%. ...
Source: SeekingAlpha
Date: July, 30 2018 08:46
Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders
Transaction to result in Nasdaq-listed company focused on developing novel products to treat central nervous system diseases Transaction expected to advance Seelos’ robust, late-stage pipeline of five programs, with near-term clinical and regulatory milestones Ownership spli...
Source: Thomson Reuters ONE
Date: July, 30 2018 08:00
Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks
Stock Research Monitor: ACHN, ATNM, and APRI LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on AMRN sign up now at www.wallstequities.com/registration . On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading...
Source: ACCESSWIRE IA
Date: July, 02 2018 07:05
Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks
Stock Research Monitor: ATNM, AMRN, and APRI LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want a free Stock Review on AXON sign up now at www.wallstequities.com/registration . In today's pre-market research, WallStEquities.com scans Actinium Pharmaceuticals Inc. (NYSE AMER: ATNM ),...
Source: ACCESSWIRE IA
Date: June, 04 2018 07:30
Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results:
Company Pursuing U.S. Vitaros Partnership and Strategic Alternatives SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company seeking to advance innovative medicines in urology and rheumatology, today reported financial results for t...
Source: Thomson Reuters ONE
Date: May, 03 2018 16:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-130.290.320.339670.291,817,687
2018-12-120.2950.28920.2950.28149,932
2018-12-110.270.28240.2890.27482,009
2018-12-100.2950.280.2950.27355,891
2018-12-070.30730.28010.30730.27371,320

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-13286,276513,40755.7601Short
2018-12-1224,63661,26540.2122Short
2018-12-1143,13595,55945.1397Short
2018-12-1023,67131,44275.2847Short
2018-12-0723,572191,66612.2985Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on APRI.


About Apricus Biosciences, Inc. (NASDAQ: APRI)

Logo for Apricus Biosciences, Inc. (NASDAQ: APRI)

Not available

 

Contact Information

 

 

Current Management

  • Y. Joseph Mo / President, CEO
  • Joseph M. Warusz / CFO

Current Share Structure

  • Market Cap: $6,821,354 - 05/14/2018
  • Issue and Outstanding: 23,441,080 - 04/27/2018

 


Recent Filings from (NASDAQ: APRI)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 17 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 06 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 06 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 28 2018

 

 


Daily Technical Chart for (NASDAQ: APRI)

Daily Technical Chart for (NASDAQ: APRI)


Stay tuned for daily updates and more on (NASDAQ: APRI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: APRI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in APRI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of APRI and does not buy, sell, or trade any shares of APRI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/